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Abstract 
Spectroscopic diagnostics have been shown to be an effective tool for the analysis and discrimination of 
disease states from human tissue. Furthermore, Raman spectroscopic probes are of particular interest as 
they allow for in vivo spectroscopic diagnostics, for tasks such as the identification of tumour margins 
during surgery. In this study, we investigate a feature-driven approach to the classification of metastatic 
brain cancer, glioblastoma (GB) and non-cancer from tissue samples, and we provide a real-time 
feedback method for endoscopic diagnostics using sound. To do this, we first evaluate the sensitivity and 
specificity of three classifiers (SVM, KNN and LDA), when trained with both sub-band spectral features 
and principal components taken directly from Raman spectra. We demonstrate that the feature extraction 
approach provides an increase in classification accuracy of 26.25 % for SVM and 25 % for KNN. We 
then discuss the molecular assignment of the most salient sub-bands in the dataset. The most salient sub-
band features are mapped to parameters of a frequency modulation (FM) synthesizer in order to generate 
audio clips from each tissue sample. Based on the properties of the sub-band features, the synthesizer 
was able to maintain similar sound timbres within the disease classes and provide different timbres 
between disease classes. This was reinforced via listening tests, in which participants were able to 
discriminate between classes with mean classification accuracy of 71.1%. Providing intuitive feedback 
via sound frees the surgeons' visual attention to remain on the patient, allowing for greater control over 
diagnostic and surgical tools during surgery, and thus promoting clinical translation of spectroscopic 
diagnostics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Introduction 
Malignant gliomas are among the most lethal of cancers with a 20-year average reduction in life 
expectancy, the highest of any cancer and just 6% of adults with a high grade glioma (glioblastoma (GB)) 
survive for more than 5 years’ post-diagnosis of a malignant brain tumour1,2. Brain tumours can be 
grouped into two main classes, primary and metastatic tumours. Primary brain tumours such as GB 
originate within the central nervous system (CNS) with tumour types after the glial cells to which they 
show morphological similarities3. Around 13,000 people in the UK are diagnosed with brain cancer every 
year, of which, 60% are metastatic tumours, which have originated from primary cancers outside the 
CNS4. The major primary tumours that metastasise to the brain are lung (50%), breast (15 - 25%) 
melanoma (5 - 20%) and all others (5 - 30%)5. The identification of the organ of origin increases the 
efficiency of treatment and patient survival, however in approx. 15% of metastatic cases the primary 
location is unknown6. 
 
Following detection of a brain tumour by conventional imaging modalities (e.g. MRI) a biopsy and 
resection is a likely course of action, particularly for high grade and metastatic cancers. Complete tumour 
removal during surgery is a strong indicator of recurrence-free survival with increased median overall 
survival for those patients undergoing macroscopic resection compared to tumour debulking and biopsy7. 
The recurrence rates for Grade II and II meningiomas are 13.8% with complete resection and 46.7% for 
incomplete resection8. The current process is unable to accurately identify tumour margins and definitive 
histopathological diagnosis is generally too time consuming for responsive action during surgery. It 
should also be noted that it is often not possible to remove all of a tumour since they frequently involve 
eloquent areas of the brain and the surgery itself would leave the patient with an unacceptable 
neurological deficit e.g. hemiparesis or dysphasia. There is a pressing need for a tool that can identify 
the origin of a tumour (e.g. primary vs. metastasis) and enable the identification of tumour margins (e.g. 
brain tumour vs. normal) dynamically during surgery. 
 
Vibrational spectroscopic techniques, such as Raman and FTIR, have been shown to be sensitive to the 
hallmarks of cancer9-15. They are non-destructive, simple to operate and require minimal sample 
preparation. Inelastically (Raman) scattered light from molecules under irradiation is wavelength-shifted 
with respect to the incident light by molecular vibrations. The Raman spectrum is complementary to that 
of IR where incident light is absorbed at the resonant frequency of a particular bond or group. Different 
biomolecules exhibit distinct responses to varying wavelengths of light; the resulting spectrum can be 
thought of as a ‘fingerprint’ or ‘signature’ of the sample. Spectroscopic analysis allows the objective 
classification of biological material on a molecular level12. Several groups have investigated the use of 
Raman spectroscopy to discriminate brain tissue. In particular, Gajjar et al. reported the ability of Raman 
spectroscopy to differentiate between brain tumour and healthy brain tissue16. They observed successful 
discrimination between different brain tumour types in their study. They reported that cancerous brain 
tissue could be discriminated from healthy brain tissue on low-E substrates based on spectral peaks at: 
997 cm-1 (phospholipids and glucose-I-phosphate), 1077 cm-1 and 1446 cm-1 (lipids and proteins), 1241 
cm-1 (amide III), 1460 cm-1 (cytosine) and 1654 cm-1 (amide I). We have previously published research 
investigating the sample preparation and use of Raman spectroscopy for spectral histopathology of 
metastatic brain cancer and primary sites of origin17,18. This study showed the use of multivariate analysis 
and visual inspection of Raman spectra from brain tumour tissue samples. Using the ratio of 620 cm-1 
(C-C twisting mode of phenylalanine) to 782 cm-1 (cytosine uracil ring breathing mode of nucleotide) 
versus 721 cm-1 (symmetric choline C-N stretch/adenine) to 620 cm-1, disease discrimination was 
achievable at sensitivities and specificities of 85.71 - 100 % and 94.44 – 100 % respectively.  
 
Raman spectroscopy for clinical diagnostics has seen concerted development of Raman probes to identify 
and delineate tumour margins during surgery. Proof-of-concept studies were initially conducted upon 
fixed tissue, predominately Formalin Fixed Paraffin Processed (FFPP), that are routinely used for 
histopathological analysis; however, due to the biochemical alterations that occur as a consequence of 
chemical fixation, largely evident in the lipid associated spectral regions, investigation in fresh tissue is 
spearheading clinical implementation19. Pioneering work has shown the applicability of fibre-optic 
Raman probes for intra-operative analysis of the brain20 (with recent patient preliminary trials performed 
during brain surgery), stomach21, oesophagus22 and lymph nodes23. Mahadevan-Jansen24 has reported the 
successful discrimination of cervical precancers using in vivo Raman spectroscopy and Krafft has 
recently shown the in vivo detection of metastases in mouse brain25. Optical biopsy of breast tissue has 
also allowed rapid discrimination of cancerous tissues and has also derived diagnostic markers for cancer 
prognosis26-28. These examples highlight the potential of Raman probes in the clinic; however, clinical 
implementation still remains a significant challenge. Primarily, data feedback is too slow and reliant 
upon interpretation of complex spectra or multivariate analysis (MVA) plots, requiring additional 
expertise at the point of interpretation. Although rapid spectral acquisition and automated analysis is 
possible, a typical diagnosis of a small spectral dataset could take up to several minutes due to the 
complexity and quality of the Raman spectrum. These time constraints are further amplified when larger 
datasets are acquired, such as those obtained in spectroscopic imaging experiments. A process that 
enables real-time, easy to understand feedback of the molecularly specific data to the surgeon during 
surgery would prove extremely useful. 
 
In a recent study we have introduced a method for subjectively discriminating between spectra by 
synthesising sounds from vibrational spectroscopic data for the detection of differentiated and 
undifferentiated stem cells29. In this study, we demonstrate a real-time methodology for band-wise 
feature extraction, sound synthesis and feedback from Raman spectra to enable the real-time 
discrimination of metastatic brain tumours, primary brain tumours (GB) and normal tissue. By extracting 
features prior to diagnosis via MVA, the analytical time constraints are reduced, and a real-time feedback 
is possible. Furthermore, by using sonification combined with a Raman probe, surgeons are able to 
analyse tissue during surgery, providing a responsive diagnostic environment for patient benefit. 
Providing data feedback via sound frees the surgeons' visual attention to remain focused on the surgical 
resection and eases translation of Raman spectroscopy as a surgical aid.  
 
  
2. Materials and Methods 
Our primary experiment investigates the influence of band-wise spectral feature extraction on brain 
tumour classification, when compared against existing dimensionality reduction methods. To do this, we 
compare the classification accuracies of three classifiers when presented with sub-band features and 
principal components. The three classifiers chosen for this experiment were a K-Nearest Neighbour 
classifier (KNN), a Support Vector Machine (SVM) and a Linear Discriminant Analysis classifier 
(LDA). Each for the classifiers were trained with the same dataset partitions and cross-validated. 
Additionally, in order to show the salience of the selected features and the relevance of corresponding 
spectral bands, we analyse the magnitude spectra and run feature selection on the extracted features. To 
demonstrate the efficacy of the feature-driven approach to tissue sample classification, we then use data 
sonification to generate audio samples, thus illustrating the technique's potential for use with in vivo 
auditory feedback. To do this, synthesized audio clips are generated for each of the tissue samples using 
a frequency modulation (FM)-synthesis technique, then subjectively evaluated by non-specialist 
participants via listening tests. 
 
2.1 Dataset 
Tissue sections were obtained from FFPP tissue blocks from the Brain Tumour North West (BTNW) 
bio-bank and were then cut using a microtome to a thickness of 10µm and placed onto CaF2 (Crystran, 
UK) substrates for spectroscopic measurements under ethical approval (BTNW/WRTB 13_01). A total 
of 48 tissue samples were obtained from 41 patients, 7 of whom produced normal brain samples, 5 of 
whom produced World Health Organisation (WHO) grade IV GB brain tumour samples and 29 of whom 
produced metastatic brain cancer samples. All tissue sections were placed onto CaF2 substrates were de-
waxed using 3 x 5 minute baths of Histoclear, followed by 3 x 5 minute baths of ethanol. 
 
Raman spectroscopic measurements were carried using a Horiba Jobin-Yvon LabRAM HR800 
spectrometer, with an air-cooled CLDS 785 nm laser, combined with a single edge filter (cut off 100 cm-
1 and an output power of 300 mW. Spectra were acquired using a 0.75 numerical aperture x60 objective 
(LUMPlanFLN, Olympus) immersion lens with the confocal hole set to 100 µm for spectral acquisition. 
Immersion Raman spectroscopy was carried out by submerging the tissue placed onto CaF2 substrates 
into deionised water during spectral collections. In total, 952 spectra were collected from the tissue set 
and within-class samples were averaged in groups of 4 to mitigate against noise. For the normal tissue 
samples, 157 samples were averaged to 39 spectra, the GB samples were averaged from 127 to 31 spectra 
and the metastatic samples were averaged from 668 to 167 samples, resulting in a dataset of 237 spectra, 
as shown in Figure 1. 
 
 Figure 1. All spectra from the full spectral data set, where the blue spectra represent normal tissue, the 
green spectra represent metastatic and the red spectra represent GB tissue samples, off-set for clarity. It 
is clear that spectra cannot be easily differentiated as diseased without further interrogative analysis. 
2.2 Data Preprocessing 
Pre-processing was carried out on the raw data using LabSpec 6 spectroscopy software suite (HORIBA 
scientific) and SpecToolbox: an empirically developed Matlab toolbox, made especially for the 
processing and analysis of vibrational spectroscopy data. The raw spectra exhibit a low frequency 
oscillating band, which the Raman bands sit on, often referred to as the spectral background. This is 
considered to be a direct result of morphology dependent scattering of the incident light and Raman lines 
that cause non-collimated entry into the spectrometer as stray light when using lasers above 500 nm. 
Although the use of an immersion lens reduced the light scattering phenomenon through liquid to tissue, 
producing a better refractive index matching than air to tissue, low frequency spectral backgrounds were 
still present in the raw data recorded using the immersion lens. To correct for this, LabSpec 6 software 
was used to subtract a fitted fifth order polynomial from each recorded spectrum (5th order polynomial 
fit and 7 points of smoothing), producing flat baselines for all data recorded, which is essential when 
comparing spectra using multivariate analysis. Paraffin Raman peaks situated at 882-912 cm-1, 1051-
1071 cm-1, 1115-1143 cm-1, 1163-1187 cm-1, 1284-1305 cm-1 and 1407-1501 cm-1 were also removed 
from the spectra to account for any residual paraffin remaining in the FFPP tissue14. Data was normalised 
before spectral analysis so as to ensure that there is a commonality between the spectra being compared 
through adjusting each peak in each spectrum to its own internal standard. In this case vector 
normalisation was chosen, where each wavenumber absorption variable of the spectrum is squared and 
summed, then divided by the square root of the total, thus scaling all spectra 
 
2.3 Feature Extraction and Variable Ranking 
 Recent studies involving the spectroscopic analysis of pathological samples adopts a linear 
dimensionality reduction approach to feature subset derivation as a precursor to classification using a 
supervised learning algorithm18, 30, 31. Generally, this includes the projection of datapoints in a Raman 
spectrum onto a lower dimensional subspace using a technique such as PCA coupled with a kernel-based 
classifier such as a support vector machine (SVM). Due to the limitations of real-time analysis, we 
investigate alternative feature derivation techniques in an attempt to reduce the computational load, thus 
providing us with a system capable of reacting to changes in cell-type by providing auditory feedback to 
the user with minimal delay time. To do this we propose the extraction of the most discriminatory 
characteristics from each spectrum using common statistical techniques and domain knowledge. This 
involves the extraction of sub-band features from each of the spectra in our dataset, followed by an 
analysis of feature saliency using an information-gain-based feature selection algorithm. 
 
In order to capture the discriminatory characteristics of each spectrum, we employed sub-band 
decomposition, where the data in each band represents a region of spectral interest bounded by two 
predefined bins. The bands were selected subjectively, based on their association with a predefined 
molecular vibration. The global characteristics of each spectrum were calculated using broadband 
features taken from all available wavenumbers, with a lower bound of 400 cm-1 and an upper bound of 
1800 cm-1. In order to remove redundant information, statistical descriptors were taken from each band 
with the intention of representing the spectral shape and energy in a low-dimensional form. The spectral 
energy of each band was estimated using a peak measurement and Root Mean Squared (RMS) Energy. 
To represent the spectral shape of each band, standard statistical moments were extracted; these include 
spectral centroid, skew and kurtosis. Here, the centroid (given in Eq. 1) acts as a weighted mean of the 
spectral band, hence representing a central point. 
 
 
 
The skew (given in Eq. 2) defines the asymmetry of a band. 
 
 
 
The kurtosis (given in Eq. 3) describes the extent to which a band exhibits a central peak. 
 
(1) 
(2) 
  
In each of the equations, ai denotes the ith Raman coefficient, wi represents the ith wavenumber and σ is 
the standard deviation of the distribution. Once extracted, the features are vector normalised to allow for 
transferability and comparisons are made using paired inter-band ratios. This allows us to not only 
analyse the behaviour of single-band characteristics over each target class, but it allows us to preserve 
any first order interdependencies that may exist between pairs of bands. To investigate the salience of 
each feature, the single band and inter-band features are concatenated to form a feature matrix and 
variable ranking is applied using information gain. This involves comparing the distribution of each 
feature, taken across all training samples for a given target class with each of the other target classes for 
the same feature. The result is a list of features, ranked by their saliency with the target class vector. We 
can then apply a threshold to remove features that fall below a desired level of salience, leaving us with 
a lower-dimensional representation of the spectra. Once this is done, we evaluate the performance of the 
highest scoring features using a non-linear classifier and compare them to existing methods of feature 
derivation.  
 
2.4 Classification 
In order to evaluate the performance of sub-band feature extraction, three classifiers (KNN, SVM and 
LDA) are trained with the first ten principal components (chosen as they retain >90% of the variance in 
the data), then with empirically derived features. The prediction errors are then compared including the 
sensitivities and specificities of each model. The first model KNN is an instance-based classifier, selected 
for its simplicity. The technique uses Euclidean distance to map a datapoint to a tissue group during a 
testing phase, based on the corresponding classes of the K-nearest datapoints. In our experiment, we 
optimise K to 5 by running an iterative error reduction procedure with the labelled data. Secondly we use 
an SVM classifier with a Radial Basis Function (RBF) kernel, a technique that has proven to be 
successful with spectroscopic data, when trained with spectral principal components3, 30, 31. The cost (C) 
and gamma (γ) parameters of the RBF kernel were optimised via an iterative training procedure and 
empirically set to 362.03 and 0.003 respectively. The final classification method uses LDA, a form of 
multivariate analysis that attempts to maximise the inter-class variance based on a-priori knowledge of 
class distributions. LDA has been shown to be particularly effective for the classification of Raman18, 32, 
33. With LDA classification, the preceding dimensionality reduction stage is judged to be particularly 
important due to common issues with over-fitting18, 33. 
 
In the proposed topology, the PCA phase is compared to sub-band feature extraction by using both types 
of data as a precursor to the model training phase. In the PCA-based models, the number of loadings are 
determined by the preservation of >90% variance in the data, resulting in 10 dimensions. In the feature 
extraction model, we derive an initial feature matrix of 115 variables, which is subsequently reduced to 
45 after the application of variable ranking. To compare the performance of each classifier, 10-fold cross 
(3) 
validation was used, where each test and training partition was used consistently across all three 
classifiers, with both the principal component and feature-based input types.   
 
2.5 Sonification 
In order to demonstrate a potential application of the feature-driven approach, we simulate the conditions 
of real-time auditory feedback by using a limited number of discriminatory features (defined by the 
variable ranking stage) to control the parameters of a FM synthesizer. By controlling the parameters in 
this way, we are able to provide variations in sound timbre based on the tissue samples being analysed. 
Due to the multi-dimensional nature of the spectral feature data, and the low number of parameters 
available for FM synthesis, the mapping process between spectral and auditory parameters is non-trivial. 
With a low number of features we are able to provide direct mappings to parameters such as carrier 
frequency, modulation frequency and modulation index, however the optimal number of features is 
generally higher, resulting in a trade-off between classification accuracy and complexity.  
  
To verify the performance of the sonification technique, subjective listening tests were implemented 
whereby listeners were asked to classify 30 samples based on their dissimilarity. In total, 25 listeners 
aged between 18-40 participated in the listening test, all of whom had normal hearing and some 
experience with either spectroscopic analysis or medical diagnostics. Persistent samples were presented 
in pairs, and were randomly selected from a dataset of 237 samples. The samples were chosen in equal 
quantities from one of three classes: normal, metastatic and GB. The presented pairs could be taken from 
different classes or from the same class, giving an indication of both inter-class and intra-class 
dissimilarity. Participants were asked to listen to each pair of samples and provide a similarity rating 
between 0 < n < 100, where 0 is very dissimilar and 100 is very similar. The results were then compared 
to evaluate the technique's capability of generating samples with sufficient perceptual variability. 
 
To aid in audible discrimination, a training stage was presented to the group, in which a randomised set 
of labelled samples were available to the listener, with exposed class groupings. After this, the samples 
were removed and the participants were presented with unlabelled data, which they were asked to 
partition into 3 groups of potentially varying size. Participants were not made aware of class 
representations and were asked to assign groupings based on relative similarity as opposed to the 
relationship to the training data. 
 
  
3. Results & Discussion 
 
We extract the aforementioned spectral features from 8 sub-bands in each spectrum and compare the 
bands using ratios. The spectral sub-bands chosen for this experiment, along with their molecular 
representations are presented in Table 1. Here, the bands are empirically derived based on the following 
groupings of molecular vibrations: Within B1, beta-sheet structural proteins can be observed between 
~1240 - 1260 cm-1, alpha-helix structural proteins can be observed between ~1260 - 1280 cm-1 and P=O 
asymmetric stretching vibrations due to nucleic acids can be observed at ~1220-1250 cm-1. Within B2, 
alpha-helix structural proteins can be observed at ~1650-1665 cm-1 and beta-sheet structural proteins can 
be observed between ~1665-1680 cm-1. Within B3, nucleic acids and amino acids such as tryptophan can 
be observed between ~1575-1580 cm-1, Amide III can be observed around ~1550 cm-1 and other amino 
acids are evident at ~1610 cm-1. Within B4, P=O symmetric vibrations from nucleic acids or cell 
membrane phospholipids can be observed at ~1080 cm-1 and nucleic acids are evident between ~1080-
1114 cm-1.  Within B5 amino acids such as phenylalanine have been attributed to ~1030 cm-1. Within 
B6, ring breathing vibrations from nucleic acids can be observed at ~782 cm-1. Within B7, choline (group 
(H3C)N+) can be attributed to vibrations at ~720 cm-1 and amino acids such as tryptophan are evident 
between ~740-756 cm-1. Within B8, amino acids such as tyrosine and C-C twisting vibrations from 
nucleic acids cause vibrations around ~642 cm-1 and nucleic adios are evident between ~650-680 cm-1. 
 
3.1 Feature Representation  
 
Components in B7, specifically around 721 cm-1 tentatively assigned to symmetric stretching vibration 
of choline group (H3C)N+ may provide information regarding the disease status of the sample34, 35. 
Choline makes up the head group of phosphatidylcholine, an essential phospholipid abundantly found in 
eukaryotic cell membranes15, 36 – 39. Previous studies using magnetic resonance spectroscopy (MRS) have 
shown choline content to increase in GB tissue and all primary brain tumours. The increase in choline 
signal from GB and primary brain tissue has been thought to be attributed to increased cell density as a 
result of increased cellular proliferation, and over-expression of choline transporters and choline kinase 
enzymes40 - 43. It is important to note, that due to the use of FFPP tissue in this study, any lipid related 
peaks should be tentatively interpreted due to the significant impact chemical fixation has on these 
spectral regions (ALI). 
 
In addition to the intensity around 721 cm-1 in B7, some of the metastatic spectra and all GB spectra are 
shown to have an increase in signal intensity in the 740-760 cm-1 frequency range (also encapsulated by 
B7). Activity around 750 cm-1 can be associated with the essential amino acid known as tryptophan. 
Previous studies have already documented the role tryptophan has on primary gliomas; primary brain 
tumours showing high levels of tryptophan uptake using the alpha-[(11)C] Methyl-L-tryptophan (AMT) 
as a PET tracer combined with magnetic resonance imaging (MRI)44. Similarly, Kamson et al. suggest 
that the AMT-PET tracer coupled with MR imaging has the potential to differentiate between high-grade 
gliomas and brain metastases, something which is difficult using conventional MRI45. An increase in 
spectral intensities from the Raman bands situated around 750 cm-1 (B7) and between 1578-80 cm-1 (B3), 
from spectra recorded from GB tissue, suggests agreement between our data and studies using the AMT-
PET tracer to distinguish GB brain tumours, indicating increased tryptophan levels. However, a Raman 
band situated around 750 cm-1 may also be associated with molecular vibrations from lactic acid. 
 
Activity around 782 cm-1 in B6 can be tentatively assigned to ring breathing vibrations from nucleotides 
of DNA and RNA (uracil, thymine and cytosine ring breathing vibrations)15, 38. An increase in Raman 
scattering intensity in this region has previously been associated with a greater concentration of nucleic 
acids. An increase in nucleic acids present in cancerous tissue can again be correlated with an increase 
in cell density as a consequence of increased cellular proliferation18, 47, 48. This may also explain why 
spectra recorded from cancerous tissue samples show increases in signal from Raman bands situated at 
~650 (B8), ~1100 (B4), 1220-1250 (B1) and ~1575 cm-1 (B3). Vibrations around B3 have previously 
been attributed to vibrations of molecules from nucleic acid molecular structures48. A study by Wang et 
al., investigating cancerous bladder tissue with Raman spectroscopy, also showed intensity around the 
782 cm-1 region in B6 to be significantly elevated from cancerous tissues when compared against normal 
tissue spectra49. 
 
Spectral differences can also be observed at Raman bands attributed to proteins. Figures 2 and 3 both 
show that cancerous tissue spectra have a different Raman band structure to the normal tissue spectra 
from the Amide III band (B1). Here, cancerous Raman spectra exhibit an increased intensity between 
1220-1260 cm-1, shifting the overall central energy position of the band to ~1255 cm-1, whereas normal 
spectra have greater spectral intensity at ~1265-1270 cm-1, shifting the central position of the Raman 
band to a higher vibrational frequency. These shifts are captured using the spectral centroid feature, 
potentially explaining the salience of features 1 and 4 (the centroid B1/B4 and the centroid of B1 
respectively), as listed in Table 2. This may suggest that both metastatic and GB brain tissue has an 
increase in concentration of beta-structural proteins than alpha-helix structural proteins. The increased 
variance depicted in metastatic and GBM tissue samples in Figure 3, may be indicative of augmented 
biological variability that would be expected in a proliferating tumour, which is effectively defined as 
uncontrolled and therefore variable growth characteristics.  
 
Our data also shows spectral differences around the amide I and II Raman bands (B1 and B2) when 
comparing diseased against normal tissue spectra. The spectral differences seen in B1 are particularly 
interesting, with metastatic cancerous tissue shifting to a higher frequency; the central energy position 
of the amide I band of metastatic cancerous tissue being ~1670 cm-1, whereas for GB and normal tissue 
spectra the centroid of the amide I band is around 1655 cm-1. From Table 2, an amide I Raman band with 
a frequency of ~1670 cm-1 suggests a protein structure conformational change as a result of disease, 
with the metastatic amide I Raman band showing a greater concentration of beta-sheet structural proteins 
than both GB and normal tissue, which are shown to have primarily alpha-helix structural proteins 
present in their tissue.  
 
Differences in conformational protein structure have been described before when using vibrational 
spectroscopy to differentiate between diseased and healthy tissue50. Gniadecka et al. also found similar 
spectral differences between cancerous and normal tissue spectra from the amide I band51. A further 
study by Gajjar et al. also showed that an increase in Raman signal intensity between 1230-1250 cm-1 
(B1) and changes to amide I secondary structure were important spectral differences when distinguishing 
normal and cancerous brain tumour tissue17. Importantly, the study showed that in cancerous tissue there 
is a shift in the position of the amide I Raman band position, moving towards to a higher frequency 
position when compared against normal tissue spectra.  
 
Table 1. List of the bands used to analyse each spectrum in the dataset along with tentative molecular 
assignment. Contribution scores were calculated from the mean feature selection from each band.  
 
 
In Table 1, band-wise contribution is calculated by taking the mean feature selection score from features 
derived from each band (including ratios). The table shows the band with the highest mean score is B7 
(consisting predominantly of Phospholipids and Amino acids), which has a value of 0.476 and the band 
with the least impact overall is B6, which consists primarily of nucleic acids. The bands with the highest 
contribution are illustrated in Figure 2, in which subtle intra-class variances can be observed between the 
spectra from each tissue group. This is reinforced in Figure 3, in which the interclass variance for B7 is 
particularly high when compared with the intraclass variance across each tissue group. This property 
suggests that the band could yield discriminatory features for classification due to positive class 
separability. In addition to this, B7 is particularly highly correlated with the 1st principal component of 
the magnitude spectrum (Figure 4). This suggests that the band represents a significant portion of the 
variance within the data as the PCA algorithm derives new features by ranking eigenvectors of the 
covariance matrix. Similarly, PC 2 is positively correlated with B1 and B3, PC3 is positively correlated 
to B5, PC4 is positively correlated to B6 and PC5 is positively correlated to B1. From Figure 3 it is also 
evident that metastatic and GBM samples exhibit an increased degree of variance within their spectra, in 
comparison to control samples.  
 
 Figure 2. Plots taken from the 3 most discriminatory spectral sub-bands, where blue spectra represent 
normal tissue samples, green spectra represent metastatic samples and red spectra represent GB samples.  
 
Figure 3. A comparison between interclass and intraclass variance exhibited by the spectra across all 
three tissue sample groups. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Plots showing the correlation between the first 5 principal components extracted directly 
from the absorption spectra and each of the spectral bins. A threshold of 0.7 correlation has been 
applied to emphasize the more positively correlated regions. 
 
Table 2 shows the 50 highest ranked features from the feature selection investigation. Here it is clear that 
Peak location (peakFreq), peak amplitude (PeakAmp) and spectral centroid (Centroid) were salient 
descriptors, particularly when extracted from bands B1, B4 and B7. 88% of the highest 50 features were 
inter-band ratios, suggesting that the interaction between spectral regions is an important factor in 
discriminating between classes. This is significant, given that linear dimensionality reduction techniques 
such as PCA do not necessarily model complex interactions between spectral bins. 
 
Table 2. An ordered list of the top 50 features used for classification, derived using a feature selection 
process based on information gain. 
 
 
In order to evaluate the salience of the sub-band feature extraction approach, we compare the model's 
classification accuracy, including sensitivity and specificity to other common protocols such as the 
reduced dimensionality model presented in recent studies using an SVM with PCs taken directly from 
the spectral coefficients31, or using an LDA-based classifier52. To do this, 10-fold cross validation was 
applied to the dataset and the PCs were substituted for ranked feature vectors. Overall, this significantly 
improved the accuracy of both the KNN and the SVM-based classification techniques, and had a small 
negative effect on the LDA-method. For the KNN classifier, the mean accuracy increased by 25% from 
66.02% to 91.02%, with a P-value of 0.00001. The feature extraction approach improved the SVM 
classification accuracy by 26.25% from 70.76% to 97.01%, with a p-value of 0.000001. Finally, the mean 
classification accuracy of the LDA classifier dropped from 96.54% to 95.38% (-1.16%), with a p-value 
of 0.193, thus the difference is deemed to be negligible. The results of the classification experiment are 
presented in Figure 5. 
 
To further examine the effects of feature extraction on tissue classification, the sensitivity (rate of 
correctly classified positive predictions) and specificity (rate of correctly classified negative predictions) 
were measured across each tissue group, show in Table 5. The results show that both sensitivity and 
specificity are generally improved through feature extraction for the KNN and SVM based classifiers, 
and slightly reduced using LDA. For the KNN technique, the mean improvement is 28.21% for 
sensitivity and 14.07% for specificity, for SVM, the mean improvement is 57.06% for sensitivity and 
32.96% for specificity and for LDA the mean reduction in sensitivity is 3.32% and the mean reduction 
in specificity is 1.78%. When measured across all three types of classification, the class with the highest 
mean sensitivity is the metastatic group with 91.36% accuracy, and the class with the highest specificity 
is the GB tissue group, with 96.19% accuracy.  
 
Overall, the performance of feature-based classification is promising, with a significant improvement in 
classification evident in KNN and SVM techniques (+25% and +26.25% increase in classification 
accuracy) and a negligible decrease in accuracy for the PC-LDA technique (-1.16%). This suggests that 
the process of extracting statistical attributes from each Raman spectrum provides a suitable alternative 
to reducing its dimensionality using PCA. This means that not only are we able to rapidly generate inputs 
to a classifier, but we are also able to expose more information regarding the underlying molecular 
contributions. This is due to the relative ambiguity of each principal component when compared against 
the spectral shape descriptors, derived using statistical moments.   
 
 
  
 
Figure 5. Comparison between PCA and feature-driven classification, measured across three classifiers 
using 10-fold cross validation, with randomly assigned training and testing test partitions. 
 
Table 3. Sensitivity and specificity scores for each tissue type when analysed using KNN, SVM and 
LDA-based classification. For each method, the inputs were derived using both PCA and sub-band 
feature extraction. Here, the PC and Fe prefixes respectively indicate the use of PCA and feature 
extraction.  
 
 
 3.2 Data Sonification 
Sonification was performed by mapping the top five features from the feature extraction experiment to 
parameters of an FM Synthesizer. Here, the B1/B4 Centroid, B2/B8 Peak Amplitude, B2/B7 Peak 
Frequency, B1 Centroid and B8/B2 Peak Amplitude were used to control the f0, modulation index, 
modulation frequency, decay time, amplitude and sample-length parameters of the FM-synthesizer 
respectively. Using these features, the audio samples generated using the technique were intended to 
have different sound timbre between tissue groups and similar timbre within tissue groups. An example 
audio clip from each of the groups is shown in Figure 6, this illustrates the sound spectra of each audio 
sample using a spectrogram representation. 
 
 
Figure 6. Spectrogram plots showing the log Short-Term Fourier Transform (STFT) of three audio 
samples, generated from each of the tissue sample classes using the FM Synthesis-based sonification 
technique. The window size of the STFT was set to 1024 samples, with a 64 sample overlap  
 
To subjectively evaluate the synthesized audio samples, participants were asked to discriminate between 
three sample groups, based on the timbre of each sample. The results from the test show that the mean 
classification accuracy was 71.1%, with a mean variance of 3.4% measured across participants (Figure 
7). The tissue type that was easiest to audibly classify was the metastatic group, which had a mean 
classification accuracy of 86.7%, this was followed by the GB group, which had a mean score of 72.2% 
and the normal group, which had a mean classification accuracy of 54.4%, this suggests the metastatic 
is significantly easier to discriminate, with a p-value of 0.000018. 
 
In order to generate audible feedback, thus providing clinicians and surgeons with multimodal feedback, 
potentially in real-time, the features with the highest contribution were mapped to the parameters of an 
FM synthesizer. To do this, the centroid of B1/B4, peak amplitude of B2/B8, peak frequency of B4/B7, 
centroid of B1 and peak amplitude of B8/B2 were mapped to the fundamental frequency, modulation 
frequency, modulation index, envelope (central peak), and loudness. Although the reduced feature subset 
is able to yield accuracies of (88.99% SVM) and (71.35% LDA), the subjective classification accuracy 
based on the sonified samples is comparatively low at 71.77%. Whilst this is not a significant reduction, 
it suggests there is scope for improvement to either the feature mapping process, potentially involving 
the integration of a higher-dimensionality feature subset to the synthesis parameter space, or a 
modification to the sonification methodology. The subjective nature of this approach may contribute to 
this level of performance, due to the effects of age, sex, ear sensitivity as well as emotional impacts that 
will affect the performance of each listener.  A larger study interrogating a wider cohort may approach 
this issue and improve classification levels. This future study should also aim to address the users of this 
auditory feedback approach, primarily neurosurgeons, and thus the features of this demographic should 
be matched accordingly.  
 
 
 
Figure 7. The accuracy of brain cancer identification from a test cohort of 20 people, using only sound 
timbre as a discriminatory aid.  
 
 
 
  
5.0 Conclusion 
 
This feature driven technique is shown to improve the mean classification accuracy of a KNN classifier 
by 25% and an SVM classifier by 26.25%, when used as an alternative to spectral dimensionality 
reduction (PCA). The technique is also shown to perform similarly to PCA, when used in conjunction 
with an LDA classifier, exhibiting a negligible increase in mean error (1.16%). As feature extraction 
allows us to observe direct relationships between the classifier inputs and the Raman bands, we are able 
to hypothesise that there are relationships between molecular groupings and the class assignment of 
samples. In particular, the variance in B7 represents changes in choline and tryptophan and intensity in 
B6 can be attributed to ring breathing vibrations from nucleotides of DNA and RNA. Our results also 
correlate with previous literature, suggesting that B3 exhibits tissue-class variation due to varying levels 
of tryptophan between GB and metastatic cancers46. As an application of the feature extraction technique, 
we show that sonification can be used to create audio samples from a reduced subset of the extracted 
features using FM synthesis, thus enabling auditory feedback in near real-time. After implementing 
listening tests with 25 participants, the mean subjective classification accuracy was 77.1%. The features 
were selected via a variable ranking stage (using information gain) and yielded a mean accuracy of 
80.17% when measured across all three classifiers.  
 
This investigation presents an alternative method of deriving classifier input-data from Raman spectra 
and demonstrated that it is suitable for the sonification of cancerous and noncancerous tissue samples. 
Our results suggest that a feature selection approach as opposed to a dimensionality reduction, both aids 
classification efficacy, but also reduces computational burden. In doing so, in vivo spectroscopic 
diagnosis in a surgical environment is increasingly achievable. By depicting that this diagnostic output 
can also be converted to auditory feedback in an effective manner, we illustrate a potential translational 
technique that may aid a clinician during endoscopic procedures.  
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